Human immune deficiency virus (HIV) replicates by conversion of the RNA genome into the double‐stranded DNA provirus. The reverse transcriptase is not the only enzymatic function crucial in DNA‐provirus synthesis. A viral‐coded RNase H activity which specifically degrades RNA in RNA‐DNA hybrids has been shown to be essential as well. Here we demonstrate that the HIV‐reverse transcriptase which consists of a two‐polypeptide complex, p66 and p51, copurifies with an RNase H activity which exhibits properties of a processive exonuclease. Only the p66 molecule, not p51, is active as polymerase as evidenced by activated gel analysis. p66 exhibits RNase H activity when precipitated as immune complex by a monoclonal antibody raised against a bacterially expressed carboxy‐terminal portion of p66. The monoclonal antibody which does not interfere with enzyme activity also precipitates a second population of molecules with RNase H activity which is of low mol. wt, p15. This RNase H appears therefore to be derived from the carboxy terminus of p66 during processing to the p51 polypeptide. It exhibits low template‐binding ability and is of a non‐processing mode of action which may be due to the absence of the reverse transcriptase domain. These results lend experimental support to the hypothesis that the RNase H gene maps at the carboxy terminus of the reverse transcriptase. Since both RNase H populations are virus‐coded they may be essential for retrovirus replication in general and useful targets for chemotherapeutic agents.

Retroviruses code for a specific protease which is essential for polyprotein precursor processing and viral infectivity. The HIV‐specific protease has been predicted to be an aspartic protease which is located at the amino terminus of the pol gene. We have prepared several constructs for bacterial expression of the protease. Two of them span the whole protease region and result in its autocatalytic activation. Analysis of the dynamics of this activation indicates a two‐step process which starts at the carboxy terminus and ends at the amino terminus of the protease. The activated protease is a molecule of 9 kd as evidenced by monoclonal antibody in immunoblot analysis. A construct in which the carboxy terminus of the protease is deleted results in a stable, enzymatically inactive 27‐kd protein which proved useful as substrate since it contains one of the predicted cleavage sites. The stability of this protein indicates that the carboxy‐terminal sequences of the protease are essential for its activity and its autocatalytic activation. The protease which is very hydrophobic was solubilized by acetone treatment and passaged over ultrogel and propylagarose columns for partial purification. It elutes as a dimer and tends to aggregate. It is inhibited by pepstatin A in agreement with its expected active site and its theoretical classification as aspartic protease. Cleavage of the gag precursor results in the mature capsid protein, p17. The protease does not, however, cleave the denatured 27‐kd substrate or the denatured gag precursor. Therefore its specificity appears to be not solely sequence‐ but also conformation‐dependent. This property needs to be taken into account for the development of protease inhibitors for therapy of AIDS.

No abstract

No abstract

No abstract